SH2 domain-containing protein tyrosine phosphatase 2 and focal adhesion kinase protein interactions regulate pulmonary endothelium barrier function.

Abstract

Enhanced protein tyrosine phosphorylation is associated with changes in vascular permeability through formation and dissolution of adherens junctions and regulation of stress fiber formation. Inhibition of the protein tyrosine phosphorylase SH2 domain-containing protein tyrosine phosphatase 2 (SHP2) increases tyrosine phosphorylation of vascular endothelial cadherin and β-catenin, resulting in disruption of the endothelial monolayer and edema formation in the pulmonary endothelium. Vascular permeability is a hallmark of acute lung injury (ALI); thus, enhanced SHP2 activity offers potential therapeutic value for the pulmonary vasculature in diseases such as ALI, but this has not been characterized. To assess whether SHP2 activity mediates protection against edema in the endothelium, we assessed the effect of molecular activation of SHP2 on lung endothelial barrier function in response to the edemagenic agents LPS and thrombin. Both LPS and thrombin reduced SHP2 activity, correlated with decreased focal adhesion kinase (FAK) phosphorylation (Y(397) and Y(925)) and diminished SHP2 protein-protein associations with FAK. Overexpression of constitutively active SHP2 (SHP2(D61A)) enhanced baseline endothelial monolayer resistance and completely blocked LPS- and thrombin-induced permeability in vitro and significantly blunted pulmonary edema formation induced by either endotoxin (LPS) or Pseudomonas aeruginosa exposure in vivo. Chemical inhibition of FAK decreased SHP2 protein-protein interactions with FAK concomitant with increased permeability; however, overexpression of SHP2(D61A) rescued the endothelium and maintained FAK activity and FAK-SHP2 protein interactions. Our data suggest that SHP2 activation offers the pulmonary endothelium protection against barrier permeability mediators downstream of the FAK signaling pathway. We postulate that further studies into the promotion of SHP2 activation in the pulmonary endothelium may offer a therapeutic approach for patients suffering from ALI.

• Authors: Havovi Chichger, Julie Braza, Huetran Duong, Elizabeth O Harrington
• Journal: American journal of respiratory cell and molecular biology (Am J Respir Cell Mol Biol) Vol. 52 Issue 6 Pg. 695-707 (Jun 2015) ISSN: 1535-4989 [Electronic] United States
• PMID: 25317600 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Lipopolysaccharides
• Focal Adhesion Protein-Tyrosine Kinases
• Protein Tyrosine Phosphatase, Non-Receptor Type 11

Topics

• Acute Lung Injury (enzymology, immunology)
• Animals
• Capillary Permeability
• Cells, Cultured
• Endothelial Cells (enzymology, immunology)
• Endothelium, Vascular (pathology)
• Focal Adhesion Protein-Tyrosine Kinases (metabolism)
• Lipopolysaccharides (pharmacology)
• Lung (blood supply)
• Mice, Inbred C57BL
• Microvessels (pathology)
• Phosphorylation
• Protein Interaction Maps
• Protein Processing, Post-Translational
• Protein Tyrosine Phosphatase, Non-Receptor Type 11 (metabolism)
• Rats
• Regional Blood Flow